Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383449 | 0.77 | ALDH1A1 (0.42) | GPR35MAOAMGAMALDH1A1MAPT | |
| SCHEMBL2371483 | 0.73 | NPC1 (0.46) | MAOAPTGS2ALDH1A1MAPTCSNK2A2 | |
| SCHEMBL8515753 | 0.73 | MAPT (0.50) | GPR35MAOAMGAMALDH1A1MAPT | |
| SCHEMBL2370587 | 0.73 | MAPT (0.54) | GPR35MAOAMGAMALDH1A1MAPT | |
| SCHEMBL21327628 | 0.70 | MAOA (0.52) | CYP1A1CYP1A2CYP1B1MAOAALDH1A1 | |
| SCHEMBL12525253 | 0.68 | MAOA (0.53) | MAOAMGAMPTGS2ALDH1A1MAPT | |
| SCHEMBL571194 | 0.67 | NPC1 (0.55) | MAOAPTGS2ALDH1A1MAPTCSNK2A2 | |
| SCHEMBL570364 | 0.67 | NPC1 (0.55) | MAOAPTGS2ALDH1A1MAPTCSNK2A2 | |
| SCHEMBL23259191 | 0.66 | GAA (0.44) | ALDH1A1MAPT | |
| SCHEMBL15470534 | 0.65 | GABRP (0.43) | MAPTCSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | GPR35 2172/4885CYP1A1 157/4885CYP1A2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.